Novo Holdings has made a €86 million investment in 21st.Bio, a Danish bioindustrial scale-up company.
21st.Bio supports bioindustrial companies with matters such as the upscaling of molecular innovation or large-scale production that can meet market demands and advance the green transition globally.
One core focal area for 21st.Bio is producing proteins and peptides that can be utilised for the food, materials and agricultural industries.
21st.Bio’s technology platform originates from selected parts of Novozymes, which provides a co-exclusive license to 21st.Bio within certain boundaries of applications.
Access to selected parts of Novozymes’ R&D platform and the investment by Novo Holdings will enable the company to expand its capabilities even further.
Thomas Schmidt, co-founder and CEO of 21st.Bio, said: “Many brilliant industrial biotech ideas never succeed, because production challenges result in too high price points for the final product. Hence, a vast number of otherwise great innovations do not make it to a scale at which they are truly relevant for the world”.
He continued: “At 21st.Bio, we can help establish the right technology for producing novel molecules and peptides and hence help innovators successfully make the difficult step from innovation to big business and impact for the planet. We have gained access to a selection of Novozymes’ unique technology platform on commercial terms, which means that a success for 21st.Bio is also a success for Novozymes.”
Søren Møller, managing partner of Novo Seeds at Novo Holdings, will join the company’s board of directors.
By Lauren Ford
Source: foodbev.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
